You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HIV-1 treatment, monoclonal antibodies

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV Trial in South Africa (VRC01.23LS, PGT121.414.LS, PGDM1400LS)

Not yet recruiting
  • HIV Infections
  • VRC01.23LS
  • +2 more
  • Cape Town, Western Cape, South Africa
  • +7 more
Jul 24, 2023

HIV/AIDS and Infections Trial in France (Recombinant human mAb (bNAbs), Placebo)

Not yet recruiting
  • HIV/AIDS and Infections
  • Recombinant human monoclonal antibody (bNAbs)
  • Placebo
  • Bobigny, France
  • +16 more
Mar 18, 2022

HIV Trial in Worldwide (VRC01, VRC01LS, VRC07-523LS)

Completed
Has Results
  • HIV Infections
  • VRC01
  • +2 more
  • Los Angeles, California
  • +13 more
Dec 19, 2022

HIV/AIDS Trial in Orlando, Boston, Houston (PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400)

Completed
  • HIV/AIDS
  • PGT121 + VRC07-523LS
  • PGT121 + VRC07-523LS + PGDM1400
  • Orlando, Florida
  • +2 more
May 6, 2022

HIV-1-infection Trial in Pathum Wan (VRC07-523LS, PGDM1400LS, N-803)

Not yet recruiting
  • HIV-1-infection
  • VRC07-523LS
  • +7 more
  • Pathum Wan, Bangkok, Thailand
  • +1 more
Mar 8, 2023

Alzheimer Trial (Lecanemab)

Not yet recruiting
  • Alzheimer Disease
  • (no location specified)
Jun 22, 2023

Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment

Recruiting
  • COVID-19 Convalescent Plasma Treatment
    • Strasbourg, France
      Service des Maladies Infectieuses et Tropicales - CHU de Strasbo
    Jun 15, 2023

    Medicare Anti-Aß mAb Coverage With Evidence Development Study

    Recruiting
    • Mild Alzheimer's Disease
    • Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
    • Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
    • Baltimore, Maryland
      Centers for Medicare and Medicaid Services
    Sep 21, 2023

    Monoclonal Gammopathy of Uncertain Significance Trial in Utrecht (Zanubrutinib Oral Product)

    Not yet recruiting
    • Monoclonal Gammopathy of Uncertain Significance
    • Zanubrutinib Oral Product
    • Utrecht, Netherlands
      University Medical Center Utrecht
    Jul 6, 2023

    Human Immunodeficiency Virus Trial in New York, Philadelphia (3BNC117-LS, 10-1074-LS, N803)

    Not yet recruiting
    • Human Immunodeficiency Virus
    • New York, New York
    • +2 more
    Jul 12, 2022

    HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)

    Completed
    • HIV Antibodies
    • VRC-HIVMAB091-00-AB
    • EDP
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Oct 8, 2022

    HIV-1-infection Trial in Umlazi (Vesatolimod, VRC07523LS, CAP256V2LS)

    Recruiting
    • HIV-1-infection
    • Umlazi, South Africa
      FRESH Clinical Research Site: Females Rising through Education,
    Jan 4, 2023

    Broadly HIV-1 Neutralizing Antibodies in HIV-infected Mbeya,

    Active, not recruiting
    • HIV/AIDS
      • Mbeya, Tanzania
        NIMR-Mbeya Medical Research Center (MMRC)
      Aug 5, 2022

      HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)

      Not yet recruiting
      • HIV-1-infection
      • Mbeya, Tanzania
        National Institute for Medical Research-Mbeya Medical Resarch Ce
      Jun 6, 2023

      HIV Trial (Teropavimab, Zinlirvimab, Lenacapavir Tablet)

      Not yet recruiting
      • HIV Infections
      • Teropavimab
      • +4 more
      • (no location specified)
      Feb 6, 2023

      Acute HIV Infection Trial in Brazil, Peru, United States (biological, other, drug)

      Not yet recruiting
      • Acute HIV Infection
      • VRC07-523LS
      • +3 more
      • Birmingham, Alabama
      • +35 more
      Jan 30, 2023

      Headache, Migraine Trial in Chicago, Naperville (Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy])

      Not yet recruiting
      • Headache, Migraine
      • Ubrogepant 50 MG [Ubrelvy]
      • Ubrogepant 100 MG [Ubrelvy]
      • Chicago, Illinois
      • +1 more
      Aug 14, 2022

      HIV-1-infection Trial in Botswana, Malawi, South Africa (3BNC117-LS-J, 10-1074-LS-J, Placebo for 3BNC117-LS-J)

      Not yet recruiting
      • HIV-1-infection
      • Molepolole, Botswana
      • +8 more
      Sep 8, 2023

      Chronic HIV Infection Trial in United States (426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum)

      Not yet recruiting
      • Chronic HIV Infection
      • 426c.Mod.Core-C4b
      • Adjuvant 3M-052-AF+Alum
      • Birmingham, Alabama
      • +6 more
      Aug 17, 2023

      COVID-19 Trial in Hong Kong (BRII-196 and BRII-198, Placebo)

      Withdrawn
      • COVID-19
      • BRII-196 and BRII-198
      • Placebo
      • Hong Kong, China
        Investigative Site 1
      Mar 1, 2022

      Allergic Rhinitis, Conjunctivitis Trial (REGN5713, REGN5714, REGN5715)

      Not yet recruiting
      • Allergic Rhinitis
      • Conjunctivitis
      • (no location specified)
      Jun 20, 2022

      Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19 Trial in San Francisco (AER002, Placebo)

      Not yet recruiting
      • Long COVID
      • +2 more
      • San Francisco, California
        UCSF/Zuckerberg San Francisco General Hospital
      Jun 2, 2023

      Coronavirus Infections Trial in Moscow (tixagevimab/cilgavimab 150+150 mg, tixagevimab/cilgavimab 300+300 mg, regdanvimab)

      Active, not recruiting
      • Coronavirus Infections
      • tixagevimab/cilgavimab 150+150 mg
      • +2 more
      • Moscow, Russian Federation
        Moscow City Clinical Hospital 52
      Aug 7, 2023

      HIV Infection Trial in United States (N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074)

      Recruiting
      • HIV Infection
      • N-803 (IL-15 Superagonist)
      • +2 more
      • Los Angeles, California
      • +11 more
      Sep 22, 2022

      HIV Trial in Philadelphia (3BNC117-LS, 10-1074-LS)

      Suspended
      • HIV Infections
      • Birmingham, Alabama
      • +5 more
      Jan 31, 2023